Lackluster Fostamatinib Results Prompt AstraZeneca To Drop Rigel Deal
This article was originally published in The Pink Sheet Daily
Executive Summary
Disappointing Phase III results have pushed AstraZeneca to end yet another partnership, leaving Rigel in a tough spot as the biotech considers how to move forward now that its largest partner has jumped ship.